Feasibility and toxicity
| Variable . | n . | % . |
|---|---|---|
| Adverse event (grades >2) | ||
| Grade 4 infection | 16 | 12 |
| Grade 3-4 mucositis | 28 | 20 |
| Grade 3 arachnoiditis | 2 | 1.4 |
| Grade 3-4 gastrointestinal toxicity | 28 | 20 |
| AML/MDS | 4 | 3.1 |
| PML | 1 | 0.7 |
| Treatment failure due to acute toxicity | 9 | 6.5 |
| Gastrointestinal hemorrhage | 1 | |
| Multiorgan failure | 1 | |
| Septicemia | 2 | |
| Unspecified toxicity | 4 | |
| Subdural hematoma | 1 | |
| Treatment-related death | 5 | 3.6 |
| Gastrointestinal hemorrhage | 1 | |
| Multiorgan failure | 1 | |
| PML* | 1 | |
| Endocarditis† | 1 | |
| Toxicity unspecified | 1 |
| Variable . | n . | % . |
|---|---|---|
| Adverse event (grades >2) | ||
| Grade 4 infection | 16 | 12 |
| Grade 3-4 mucositis | 28 | 20 |
| Grade 3 arachnoiditis | 2 | 1.4 |
| Grade 3-4 gastrointestinal toxicity | 28 | 20 |
| AML/MDS | 4 | 3.1 |
| PML | 1 | 0.7 |
| Treatment failure due to acute toxicity | 9 | 6.5 |
| Gastrointestinal hemorrhage | 1 | |
| Multiorgan failure | 1 | |
| Septicemia | 2 | |
| Unspecified toxicity | 4 | |
| Subdural hematoma | 1 | |
| Treatment-related death | 5 | 3.6 |
| Gastrointestinal hemorrhage | 1 | |
| Multiorgan failure | 1 | |
| PML* | 1 | |
| Endocarditis† | 1 | |
| Toxicity unspecified | 1 |